home / stock / entx / entx quote
Last: | $1.98 |
---|---|
Change Percent: | 1.5% |
Open: | $1.97 |
Close: | $1.98 |
High: | $2.0299 |
Low: | $1.91 |
Volume: | 118,762 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.98 | $1.97 | $1.98 | $2.0299 | $1.91 | 118,762 | 04-26-2024 |
$2 | $2.03 | $2 | $2.07 | $1.93 | 117,782 | 04-25-2024 |
$2.07 | $2.2 | $2.07 | $2.2575 | $2.01 | 163,373 | 04-24-2024 |
$2.22 | $2.05 | $2.22 | $2.24 | $1.97 | 113,415 | 04-23-2024 |
$2.05 | $1.85 | $2.05 | $2.14 | $1.8101 | 172,695 | 04-22-2024 |
$1.99 | $2.24 | $1.99 | $2.29 | $1.95 | 300,780 | 04-19-2024 |
$2.24 | $2.19 | $2.24 | $2.32 | $2.18 | 167,401 | 04-18-2024 |
$2.22 | $2.2 | $2.22 | $2.269 | $2.06 | 209,349 | 04-17-2024 |
$2.29 | $2.4 | $2.29 | $2.4856 | $2.06 | 552,937 | 04-16-2024 |
$2.52 | $3 | $2.52 | $3.22 | $2.3801 | 686,894 | 04-15-2024 |
$2.98 | $2.75 | $2.98 | $3.35 | $2.65 | 1,940,102 | 04-12-2024 |
$2.66 | $2.26 | $2.66 | $2.7 | $2.25 | 691,314 | 04-11-2024 |
$2.23 | $2.23 | $2.23 | $2.69 | $2.15 | 841,362 | 04-10-2024 |
$2.25 | $1.97 | $2.25 | $2.32 | $1.95 | 366,416 | 04-09-2024 |
$1.95 | $2 | $1.95 | $2.0499 | $1.86 | 361,068 | 04-08-2024 |
$1.985 | $1.97 | $1.985 | $2 | $1.9029 | 463,146 | 04-05-2024 |
$1.9 | $1.79 | $1.9 | $1.9899 | $1.7403 | 246,454 | 04-04-2024 |
$1.73 | $1.86 | $1.73 | $1.9154 | $1.65 | 198,203 | 04-03-2024 |
$1.86 | $1.9 | $1.86 | $1.97 | $1.69 | 320,071 | 04-02-2024 |
$1.87 | $1.7 | $1.87 | $1.95 | $1.655 | 391,545 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Entera Bio Ltd. Company Name:
ENTX Stock Symbol:
NASDAQ Market:
JERUSALEM, April 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today that data from the Phase 2 Trial of its lead clinical compound, EB613 (Oral PTH(1-34) Tab...
JERUSALEM, March 26, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of orally delivered peptides, announced today that The American Society for Bone and Mineral Research (ASBMR) announced on March 25 202...
JERUSALEM, March 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, announced today positive pharmacokinetic results from its collaborative research combining a proprietary ...